Using Your Own Bone Marrow Cells to Treat Premature Ovarian Insufficiency Through a Transvaginal Procedure with Ultrasound Guidance

What this Trial Is About

Researchers are evaluating a treatment for premature ovarian insufficiency, a condition where ovarian function declines early in women under 40 years old. This condition is marked by irregular or absent menstruation and hormonal changes such as increased gonadotropins and decreased estrogen and anti-Mullerian hormone. The study investigates the use of autologous bone marrow-derived mononuclear cells to potentially restore ovarian function without needing an oocyte donation program. The treatment involves collecting bone marrow cells from the participant under general anesthesia, concentrating these cells, and then injecting 1cc of the concentrated mononuclear cells into each ovary using a transvaginal approach guided by ultrasound. This is a single-arm interventional study where all participants receive this procedure performed by an experienced gynecologist. Participants will be monitored every four weeks for about one year to assess changes in gonadotropin hormone levels as the primary outcome. The study also involves ultrasound assessments to observe ovarian follicle development and laboratory tests for hormonal studies. The overall goal is to evaluate the safety and biological effects of the bone marrow cell injections in women diagnosed with premature ovarian insufficiency.

Treatment of Premature Ovarian Insufficiency Using Bone Marrow Cells